期刊
EUROPEAN JOURNAL OF NEUROLOGY
卷 28, 期 9, 页码 3072-3079出版社
WILEY
DOI: 10.1111/ene.14961
关键词
case-control studies; cytomegalovirus; herpesviruses; multiple sclerosis; serology
资金
- Swedish Research Council [2015-02419, 2018-03918]
- Visare Norr Fund, Northern County Councils' Regional Federation [940405]
- Research and Development Unit, Region Jamtland Harjedalen [JLL-939768]
- Margaretha af Ugglas stiftelse
- Swedish Neuro Foundation
- MS Research fund
- Swedish Research Council
- Swedish Brain Foundation
- Horizon 2020 MultipleMS Grant [733161]
The study indicates that cytomegalovirus (CMV) seropositivity is associated with a decreased risk for multiple sclerosis (MS), and there are interactions between CMV seropositivity and seropositivity against EBV and HHV-6A.
Background and purpose Epstein-Barr virus (EBV) and human herpesvirus 6A (HHV-6A) are associated with increased risk of multiple sclerosis (MS). Conversely, infection with cytomegalovirus (CMV) has been suggested to reduce the risk of MS but supporting data from presymptomatic studies are lacking. Here, it was sought to increase the understanding of CMV in MS aetiology. Methods A nested case-control study was performed with presymptomatically collected blood samples identified through crosslinkage of MS registries and Swedish biobanks. Serological antibody response against CMV, EBV and HHV-6A was determined using a bead-based multiplex assay. Odds ratio (OR) with 95% confidence interval (CI) for CMV seropositivity as a risk factor for MS was calculated by conditional logistic regression and adjusted for EBV and HHV-6A seropositivity. Potential interactions on the additive scale were analysed by calculating the attributable proportion due to interaction (AP). Results Serum samples from 670 pairs of matched cases and controls were included. CMV seropositivity was associated with a reduced risk for MS (OR = 0.70, 95% CI 0.56-0.88, p = 0.003). Statistical interactions on the additive scale were observed between seronegativity for CMV and seropositivity against HHV-6A (AP 0.34, 95% CI 0.06-0.61) and EBV antigen EBNA-1 (amino acid 385-420) at age 20-39 years (AP 0.37, 95% CI 0.09-0.65). Conclusions Cytomegalovirus seropositivity is associated with a decreased risk for MS. The protective role for CMV infection in MS aetiology is further supported by the interactions between CMV seronegativity and EBV and HHV-6A seropositivity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据